Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines

Breast Cancer Research and Treatment

Volumn 59, Issue 3, 2000, Pages 263-270

  Magklara, Angeliki ^a,b   Grass, Linda ^a   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer cell lines; Gene regulation; Hormones and cancer; Human glandular kallikrein; Kallikreins; Prostate specific antigen; Steroid hormones

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ESTRADIOL; GESTAGEN; MIBOLERONE; NORGESTREL; PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; FLUOROMETRY; GENE EXPRESSION; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; HUMAN CELL; IMMUNOASSAY; PRIORITY JOURNAL;

BREAST NEOPLASMS; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROSTATE-SPECIFIC ANTIGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEROIDS; TISSUE KALLIKREINS; TUMOR CELLS, CULTURED;

EID: 0034055647     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006304518750     Document Type: Article

References (26)

1. 1. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW: Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 35: 275-368, 1998
2. 2. Magklara A, Scorilas A, Catalona WJ, Diamandis EP: The combination of human glandular kallikrein (hK2) and free PSA enhances the discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately elevated total PSA levels. Clin Chem 45: 1960-1966, 1999
3. 3. Kwiatkowski MK, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, Tscholl R: In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic 'gray zone' of total PSA 4 to 10 ng/ml. Urology 52: 360-365, 1998
4. 4. Stenman UH: New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease. Clin Chem 45: 753-754, 1999
5. 5. Diamandis EP, Yu H: New biological functions of prostate-specific antigen? J Clin Endocrinol Metab 80: 1515-1517, 1995
6. 6. Diamandis EP, Yu H: Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 24: 275-282, 1997
7. 7. Black MH, Magklara A, Obiezu C, Levesque MA, Sutherland DJA, Tindall DJ, Young CYF, Sauter ER, Diamandis EP: Expression of a prostate associated protein, human glandular kallikrein (hK2) in breast tumors and in normal breast secretions. Br J Cancer (in press)
8. 8. Magklara A, Scorilas A, López-Otin C, Vizoso F, Ruibal A and Diamandis EP: Human glandular kallikrein (hK2) in breast milk, amniotic fluid and breast cyst fluid. Clin Chem 45: 1774-1780, 1999
9. 9. Lovgren J, Valtonen-Andre C, Marsal K, Lilja H, Lundwall A: Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J Androl 20: 348-355, 1999
10. 10. Yu H, Diamandis EP, Sutherland DJ: Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 27: 75-79, 1994
11. 11. Diamandis EP, Yu H, Sutherland DJ: Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 32: 301-310, 1994
12. 12. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJ, Levesque MA, Roagna R, Ponzone R, Sismondi P: Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55: 2104-2110, 1995
13. 13. Zarghami N, Grass L, Diamandis EP: Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer 75: 579-588, 1997
14. 14. Yu H, Diamandis EP: Prostate-specific antigen in milk of lactating women. Clin Chem 41: 54-58, 1995
15. 15. Diamandis EP, Yu H, López-Otin C: Prostate specific antigen -a new constituent of breast cyst fluid. Breast Cancer Res Treat 38: 259-264, 1996
16. 16. Hsieh ML, Charlesworth C, Goodmanson M, Zhang S, Seay T, Klee GG, Tindall DJ, Young CY: Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. Cancer Res 57: 2651-2656, 1997
17. 17. Ferguson RA, Yu H, Kalyvas M, Zammit S, Diamandis EP: Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the immulite immunochemiluminescent third generation assay: potential applications in prostate and breast cancers. Clin Chem 42: 675-684, 1996
18. 18. Black MH, Magklara A, Obiezu C, Melegos D. Diamandis EP: Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross reactivity from prostate-specific antigen. Clin Chem 45: 790-799, 1999
19. 19. Deguchi T, Dio T, Ehara H, Ito S, Takahashi Y, Nishino Y et al.: Detection of micrometastatic prostate cancer cells in lymph nodes by reverse-transcriptase-polymerase chain reaction. Cancer Res 53: 5350-5354, 1993
20. 20. Markiewicz L, Gurpide E: Estrogenic and progestagenic activities of physiologic and synthetic androgens, as measured by in vitro bioassays. Methods Find Exp Clin Pharmacol 19: 215-222, 1997
21. 21. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393-1398, 1995
22. 22. Yeh S, Miyamoto H, Shima H, Chang C: From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci USA 95: 5527-5532, 1998
23. 23. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS: Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 10: 119-131, 1996
24. 24. Hackenberg R, Luttchens S, Hofmann J, Kunzmann R, Holzel F, Schulz KD: Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Res 51: 5722-5727, 1991
25. 25. Kumar MV, Leo ME, Tindall DJ: Modulation of androgen receptor transcriptional activity by the estrogen receptor. J Androl 15: 534-542, 1994
26. 26. Hall RE, Birrell SN, Tilley WD, Sutherland RL: MDA-MB-453, an androgen-responsive human breast carcinoma cell line with a high level of androgen receptor expression. Eur J Cancer 30A: 484-490, 1994